Aerodynamically streamlined enclosure for input devices of a medication preparation system

Abstract
A system for preparing a pharmaceutical compound comprises: a scale having a platen configured for placement of an object thereon; a supporting arm comprising a first end coupled to a portion of the scale and a second end extending to a position above the platen of the scale; and an enclosure housing extending from the second end of the supporting arm and configured to house at least one input device. The enclosure housing has a curved front profile to minimize flow disturbance when the system is positioned within a flow hood.
Description
BACKGROUND OF THE INVENTION
Field of the Invention

The present invention is generally directed to an aerodynamically streamlined enclosure for housing input devices, such as a scanner and/or camera, which are part of a medication preparation system. The streamlined enclosure may be placed within a flow hood and may be positioned in the upstream airflow vicinity of a scale.


Description of Related Art

The preparation of sterile pharmaceutical compounds typically takes place in a flow hood that provides an air stream to create a clean zone. During such preparations, cameras, scanners, and/or scales may be utilized to document the preparation. These devices are typically located in a flow hood and are positioned in the upstream air flow vicinity of a scale. However, any object will create an air flow disturbance that will affect the downstream air flow of the object. If this flow disturbance is present in the upstream vicinity of a scale, for instance, it can result in inconsistent pressure or turbulent flow conditions in the vicinity of the scale's weighing surface. Depending on the level of flow disturbance, which is a function of multiple form parameters and location, this may result in the scale being unable to stabilize at all. A scale that cannot stabilize, may not be used to accurately prepare a medication, such as a sterile compounded medication. In certain cases, the flow disturbance may result in accuracy tolerances that are beyond the acceptable limits of the system for medication preparation.


Accordingly, a need exists for a smaller and/or more streamlined device that will result in a smaller flow disturbance near a scale of the system to create a higher likelihood of meeting accuracy and stability requirements.


SUMMARY OF THE INVENTION

In accordance with an aspect of the invention, provided is a system for preparing a pharmaceutical compound. The system comprises: a scale having a platen configured for placement of an object thereon; a supporting arm comprising a first end coupled to a portion of the scale and a second end extending to a position above the platen of the scale; and an enclosure housing extending from the second end of the supporting arm and configured to house at least one input device. The enclosure housing has a curved front profile to minimize flow disturbance when the system is positioned within a flow hood.


The enclosure housing may be formed of an upper portion and a lower portion. In addition, the enclosure housing may comprise a first end coupled to the second end of the supporting arm and a second end extending over the platen of the scale. At least a portion of the second end of the enclosure housing may have a height that is greater than a height of at least a portion of the first end of the enclosure housing.


The at least one input device may include an image capture device, a barcode scanner, or both. If both an image capture device and a barcode scanner are provided within the enclosure housing, the barcode scanner may be angled, such as at a 45° angle with respect to a field of view of the image capture device, with respect to the image capture device within the enclosure housing.


In accordance with another aspect of the invention, provided is a system for preparing a pharmaceutical compound. The system comprises: a computing device comprising a processor and a user interface providing an operator with instructions for preparing the pharmaceutical compound; a scale operatively coupled to the processor of the computing device; and an enclosure housing comprising an image capture device and a barcode scanner. The enclosure housing is supported by a supporting arm and coupled to a portion of the scale. The image capture device is operatively connected to the processor of the computing device and has a field of view positioned to capture an object positioned on the scale. The barcode scanner has a sensor that is offset from the scale.


The barcode scanner may be angled with respect to the image capture device within the enclosure housing. For instance, the barcode scanner may be angled at a 45° angle with respect to the field of view of the image capture device. The enclosure housing may be supported by the supporting arm such that the enclosure housing is positioned above the scale. The enclosure housing may have a curved front profile to minimize flow disturbance within a flow hood.


In accordance with yet another aspect of the invention, provided is a system for preparing a pharmaceutical compound. The system comprises: a computing device comprising a user interface providing an operator with instructions for preparing the pharmaceutical compound; and a flow hood having positioned therein: a scale operatively connected to the user interface; and an enclosure housing comprising a camera positioned to capture an image of the scale during the preparation of the pharmaceutical compound.


The enclosure housing may be positioned above the scale. The enclosure housing may further comprise a barcode scanner. The enclosure housing may have a curved front profile to minimize flow disturbance within the flow hood.


These and other features and characteristics of the present invention, as well as the methods of operation and functions of the related elements of structures and the combination of parts and economies of manufacture, will become more apparent upon consideration of the following description and the appended claims with reference to the accompanying drawings, all of which form a part of this specification, wherein like reference numerals designate corresponding parts in the various figures. It is to be expressly understood, however, that the drawings are for the purpose of illustration and description only and are not intended as a definition of the limits of the invention. As used in the specification and the claims, the singular form of “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an exemplary pharmacy preparation system for preparing a pharmaceutical compound in accordance with an embodiment of the present invention.



FIG. 2 is a perspective view of the pharmacy preparation system of FIG. 1 in a laminar flow hood having a user interface in accordance with an embodiment of the present invention.



FIG. 3 is an exploded perspective view of a portion of the pharmacy preparation system of FIG. 1 in accordance with an embodiment of the present invention.



FIG. 4 is a perspective view of a scale platen in accordance with an embodiment of the present invention.



FIG. 5 is a top view of the scale platen of FIG. 4 in accordance with an embodiment of the present invention.



FIG. 6 is a cross-sectional side view of a groove of the scale platen of FIG. 4 taken along line D-D of FIG. 5 in accordance with an embodiment of the present invention.



FIG. 7 is a perspective view of a flow hood system having an aerodynamically streamlined enclosure for input devices in accordance with an embodiment of the present invention.



FIG. 8A is a perspective visual representation of the air flow distribution within a flow hood having a scale and no enclosure.



FIG. 8B is a side view visual representation of the air flow distribution within a flow hood having a scale and no enclosure.



FIG. 9A is a perspective visual representation of the air flow distribution within a flow hood having a scale and a large blunt enclosure.



FIG. 9B is a side view visual representation of the air flow distribution within a flow hood having a scale and a large blunt enclosure.



FIG. 10A is a perspective visual representation of the air flow distribution within a flow hood having a scale and a medium sized blunt enclosure.



FIG. 10B is a side view visual representation of the air flow distribution within a flow hood having a scale and a medium sized blunt enclosure.



FIG. 11A is a perspective visual representation of the air flow distribution within a flow hood having a scale and a medium sized streamlined enclosure.



FIG. 11B is a side view visual representation of the air flow distribution within a flow hood having a scale and a medium sized streamlined enclosure.



FIG. 12A is a perspective visual representation of the air flow distribution within a flow hood having a scale and a small sized streamlined enclosure.



FIG. 12B is a side view visual representation of the air flow distribution within a flow hood having a scale and a small sized streamlined enclosure.



FIG. 13A is a perspective visual representation of the air flow distribution within a flow hood having a scale and a small sized shortened streamlined enclosure.



FIG. 13B is a side view visual representation of the air flow distribution within a flow hood having a scale and a small sized shortened streamlined enclosure.



FIG. 14 is a side view of a scale and a housing enclosure in accordance with an embodiment of the present invention.



FIG. 15 is a cross-sectional view of the housing enclosure of FIG. 14 taken along line A-A.



FIG. 16 is a cross-sectional view of the housing enclosure of FIG. 14 taken along line B-B.





DESCRIPTION OF THE INVENTION

For purposes of the description hereinafter, the terms “upper”, “lower”, “right”, “left”, “vertical”, “horizontal”, “top”, “bottom”, “lateral”, “longitudinal”, and derivatives thereof, shall relate to the invention as it is oriented in the drawing figures. However, it is to be understood that the invention may assume various alternative variations, except where expressly specified to the contrary. It is also to be understood that the specific devices illustrated in the attached drawings, and described in the following specification, are simply exemplary embodiments of the invention. Hence, specific dimensions and other physical characteristics related to the embodiments disclosed herein are not to be considered as limiting.


The invention is directed to an aerodynamically streamlined enclosure to house input devices, such as a scanner and/or a camera, that are part of a medication preparation system, such as a sterile drug compounding system. These devices are typically located in a flow hood and are positioned in the upstream air flow vicinity of a scale. The aerodynamically streamlined enclosure is designed in such a way to minimize the airflow disturbance that is created by having a device in a laminar airflow stream. This configuration allows the device to be placed in the upstream vicinity of a scale and still have an acceptable gravimetric accuracy (i.e. +/−0.05 g) and stabilization time (i.e. no more than 2 additional seconds) for verifying medication preparation purposes.


Any object will create an air flow disturbance that will affect the downstream air flow of the object. If this flow disturbance is present in the upstream vicinity of a scale it can result in inconsistent pressure or turbulent flow conditions in the vicinity of the scale's weighing surface. Depending on the level of flow disturbance, which is a function of multiple form parameters and location, this may result in the scale being unable to stabilize at all. A scale that cannot stabilize, may not be used to accurately prepare a medication, such as a sterile compounded medication. In certain cases, the flow disturbance may result in accuracy tolerances that are beyond the acceptable limits of the system for medication preparation.


A smaller and/or more streamlined device will result in a smaller flow disturbance and therefore a higher likelihood of meeting accuracy and stability requirements. The streamlined enclosure of the present invention has a form that minimizes flow disruption and drag, allowing for stable and accurate enough gravimetric readings that are required for medication preparation purposes. The streamlined enclosure of the present invention allows for required gravimetric scale accuracy and stability, while placing the input devices in the upstream airflow vicinity relative to the scale. Placing these objects (i.e. scanner and/or camera) within the scale vicinity is typically the ideal area for a number of reasons. A secondary advantage to the streamlined enclosure of the present invention is to provide and maintain a clean working environment for the sterile preparation of medications. In use, the purpose of the air stream in a flow hood is to create a clean zone for sanitary reasons. A turbulent zone created by objects near, or upstream, of the airflow may result in a potential contamination hazard during medication preparation. As a result, having an aerodynamically shaped enclosure housing for input devices minimizes the amount of laminar airflow disruption and decreases the chances of any type of contamination.


In accordance with one aspect of the present invention, a single enclosure houses at least one input device above the scale. The enclosure may house multiple input devices above the scale, such as a scanner and a camera. The enclosure is small and streamlined enough so that it has minimal effects on the stability and accuracy of the scale.


In certain cases, the input device enclosure may be positioned to the side or back of the scale and not directly provided in the upstream vicinity of the scale's weighing surface relative to airflow direction. This configuration may provide stable and accurate gravimetric scale readings since disturbed airflow would not reach the weighing surface vicinity of the scale, however, the input device would be provided in a less than ideal location. For example, if the input device is a camera, this side or back placement of the camera would most likely require photographs to be taken in a perspective view. If the input device is a scanner, this side or back placement would provide the scanner in a potentially less ergonomic location for use by a user.


In other cases, the input device may have a small enough footprint to be suitable for use without any enclosure. This configuration may provide efficient ergonomic scanning and the ability to have pictures taken from a direct top down view. This configuration may require that the housing of the device itself be optimized to provide little disruption to the air flow.


In still other cases, positioning an input device above the scale but in an orientation and/or with aid from additional air flow manipulating features could result in air that is sufficiently channeled away from the scale weighing surface so as to not have an appreciable effect on gravimetric readings of the scale. Similarly, additional airflow manipulating features could be designed to reorient disturbed air sufficiently such that when the air hits the scale weighing surface it is sufficiently deflected and/or dampened such that it does not adversely affect the stability and accuracy of the scale.


In another configuration, an enclosure may be provided around the scale so as to eliminate any type of potential airflow disturbance to gravimetric readings (i.e. a box housing used with high accuracy scales). A blunt, non-aerodynamic enclosure for the scale could fulfill gravimetric stability and accuracy requirements under a limited number of hoods since airflow patterns and flow rates vary between hoods.


In yet another configuration, a scale may be provided with high filtering for noisy environments or processing the gravimetric signal outside of the scale's logic system. This configuration could be used as a solution to achieving more accurate and stable results with blunt or non-streamlined objects.


In still another configuration, a platen of the scale may be provided in a way that minimizes the effects of airflow disturbances on the reading of the scale. Raising the device high enough above the scale could be a solution to achieving more accurate and stable results with blunt or non-streamlined objects.


The degree of sensitivity that a scale has under a typical hood used in sterile compounding is on the order of (+/−0.05 g) for a down flow rate of 55-80 cfm. To understand why this is the case, the pressure that is seen on the weighing surface of the scale and its relationship to the desired level of accuracy needs to be understood. According to simulations, the pressure that the platen (weighing surface of the scale) experiences ranges from −1.2 Pa to 0.1 Pa, with an average of approximately −0.07 Pa. To gain an accuracy of +/−0.05 g a deviation of no more than +/−0.0126 Pa can be experienced by the scale due to airflow disturbances. This is extremely small compared to the overall range of pressure that the scale experiences. Qualitatively, this magnitude is so small that a user's hand moving in the vicinity of a surface can easily induce enough air movement to result in a much greater pressure disturbance. As a result, parameters such as form location within the hood (different flow patterns in different areas) and hood brands/models were realized to have a great enough influence on the performance of the scale's stability and accuracy.


With reference to FIGS. 1-2, a pharmacy preparation system, denoted generally as reference numeral 1, assists pharmacists or non-pharmacist technicians in preparing a syringe, drug vial, or intravenous (IV) bag with one or more prescribed pharmaceutical compounds. The pharmacy preparation system is operatively connected to a user interface 3 including a computer having a processor and a stored memory, as well as a display 5 and a user input device 7, such as a keyboard, mouse, etc. A scale 9 having a scale output interface 11 may be operatively connected to the processor of the user interface 3. The scale 9 may be implemented as any suitable device for detecting a change in mass or weight when an object is placed thereon. Accordingly, the scale 9 may simply be configured as a device that sends a signal when the mass or weight of an object is greater or less than a predetermined threshold or a high-precision scale that provides an accurate reading of the weight of an object placed thereon.


In one embodiment, a barcode scanner 13 may be operatively connected to at least one of the processor of the user interface 3 and the scale 9, such that the barcode scanner 13 may scan a medication vial having a barcode that is placed onto a portion of the scale 9. In another embodiment, an image capture device 15 may be operatively connected to at least one of the user interface 3 and the scale 9, such that the image capture device 15 may take a picture of an item, such as a medication vial, IV bag, or syringe placed onto a portion of the scale 9. In one embodiment, the image capture device 15 may capture a plurality of still images or running video of items placed onto a portion of the scale 9 throughout the medication compounding process for documentation and/or subsequent review of the medication compounding process.


In still another embodiment, at least one of the barcode scanner 13 and the image capture device 15 may be at least partially enclosed within a housing 17. In certain configurations, the housing 17 may fully enclose the barcode scanner 13 and the image capture device 15. Optionally, the housing 17 may include only one of the barcode scanner 13 and the image capture device 15. In one configuration, the barcode scanner 13 may be positioned within the housing 17 such that the barcode scanner 13 may easily scan a barcode of an item placed onto a portion of the scale 9 without further manipulation by the user. In another configuration, the image capture device 15 may be positioned within the housing 17 such that the image capture device may easily capture images of an item placed onto a portion of the scale 9 without further manipulation by the user.


With specific reference to FIG. 3, the housing 17 may be formed of an upper portion 17A and a lower portion 17B which are interfaced to provide minimal surface perturbations to minimize any surface adherence of contaminants such as microbes or other pathogens. In one embodiment, the manufacturing of the housing 17 adheres to USP 797. Optical lenses 6, 8 may be fitted with the housing 17 to further ensure adherence to USP 797. In one configuration, optical lens 6 may be fitted with housing 17 in optical communication with image capture device 15. In another configuration, optical lens 8 may be fitted with housing 17 in optical communication with barcode scanner 13.


In one configuration, the barcode scanner 13 may be positioned within the housing 17 such that the barcode scanner 13 has a scanner that is offset from immediately scanning a barcode of an item placed onto a portion of the scale 9 without further manipulation by the user. In this configuration, accidental scanning is avoided. As shown in FIG. 3, the barcode scanner 13 may be positioned such that the sensor is angled with respect to a platen 31 of the scale, such as at a 45° angle by a mounting bracket 18. In this configuration, the user must actively place the objects to be scanned in range of the sensor of the barcode scanner 13. In another configuration, the image capture device 15 may be positioned within the housing 17 such that the image capture device may easily capture images of an item placed onto a portion of the scale 9 without further manipulation by the user.


The housing 17 may be positioned above a portion of the scale 9, such as supported by a supporting arm 19. As shown in FIG. 2, the pharmacy preparation system 1 may be positioned within a laminar flow hood 25 having an inlet air source 23 and an outlet air port 27 for creating a laminar flow of air within an interior 29 of the laminar flow hood 25. An exterior surface 21 of the housing 17 may have a curved front profile as shown in FIGS. 1-3 to provide it with a streamlined shape and/or a profile which is optimized to reduce disruption of the flow of air within the laminar flow hood 25.


Referring again to FIGS. 1-3, the scale 9 may include a base portion 43 which supports a platen 31 thereon. The base portion 43 houses a strain gauge load cell which measures the strain of an object placed on the platen 31, and a force transducer, such as a load cell sensor, which converts the force applied to the platen 31 into an electrical signal which may be relayed to the scale output interface 11. The base portion 43 supports the platen 31, such as a portion of the weighing surface of the scale 9, which may provide a visual indication, such as a cross recess 35, to the technician of a center, or other desired portion, of an image to be captured by the image capture device 15. This allows a technician to properly position drug compounding related medications 37 and related supplies within the field of view of the image capture device 15, such as the image capture device enclosed within the housing 17 positioned above the platen 31 of the scale 9. In one configuration, as shown in FIGS. 4-6, an upper surface 41 of the platen 31 may define a plurality of recessed grooves 39 and/or protrusions extending from a surface of the platen 31 to frictionally restrain drug compounding related medications 37 and related supplies on the upper surface 41 of the platen 31. In another configuration, the upper surface 41 of the platen 31 may include a tackifier or other frictionally enhancing surface to similarly restrain drug compounding related medications 37 and related supplies on the upper surface 41 of the platen 31. The arrangement of grooves 39 and/or protrusions may easily indicate to a user the center of the platen 31 which may be arranged to coincide with the center of the field of view of the image capture device 15. The surface of the platen 31 may be coated with a durable composition that resists degradation caused by exposure to caustic agents, such as chemotherapy compounds and drugs, as well as cleaning agents, such as bleach, isopropyl alcohol, and the like. In certain configurations, the durable composition may be an epoxy or epoxy-based paint or coating.


The plurality of recessed grooves 39 and/or protrusions extending from a surface of the platen 31 may be configured to restrain any liquid material that is accidentally spilled on the upper surface 41 of the platen 31 during a compounding procedure. The plurality of recessed grooves 39 may define a receiving well 47 (shown in FIG. 1) which serves to collect and restrain accidentally spilled material in a confined area within the platen 31 until proper disposal techniques may be employed.


In another embodiment, the platen 31 may be removable from a base unit 43 of the scale 9. In this configuration, the platen 31 may be disposable and a technician may remove and dispose of the platen 31 after a single sterile drug compounding procedure. In this configuration, calibration of the scale 9 may be required for each individual platen 31 that is engaged with the base 43. In an alternative configuration, the platen 31 may include a disposable cover layer (not shown) which may be removed and disposed of after a sterile drug compounding procedure. The disposable aspect of the platen 31 ensures that prior to each compounding procedure, the platen 31 is clean and that no contaminates may transfer to a component of the drug compounding procedure. The platen 31 may be formed of a metal, composite, or polymeric material, as is conventionally known for scale weighing surfaces. In a further configuration, each platen 31 may include a unique individual identifier 45, embedded therein or attached to a surface thereof, which may be captured in an image captured by the image capture device 15. This allows for a technician and/or subsequent reviewer of the images captured by the image capture device 15 of the drug compounding procedure to verify that the platen 31 was changed between preparations. This may provide documented proof of a technician's compliance with institutional safety and sterility requirements. In certain configurations, the individual identifier 45 may be detected by the system software to determine whether the platen 31 has been replaced at a specified interval, for example, at a specified point during a shift, a day, a preparation and/or after contamination is detected. In a further configuration, the need for a user to change the platen 31 may be shown through the user interface 3, such as through a GUI. In a further configuration, the system may include safety features such that the user may be prevented from performing a compounding procedure until the platen 31 is replaced. A user may be prevented from preparing a sterile compounding procedure using the scale 9 and the platen 31 until the use duration of the platen 31 is confirmed to be within a compliance parameter.


In a further embodiment, the platen 31 may include an absorbent material which may absorb accidentally spilled material until proper disposal techniques may be employed. In a further configuration, at least one receiving well 47 of the platen 31 may include the absorbent material therein.


In certain situations, such as an aerosolation, it may be difficult for a technician to determine whether a cytotoxic material has been accidentally released from a container. Accordingly, the upper surface 41 of the platen 31 may include a coating layer which provides a visual indication, such as a color change, in response to fluid contacting the coating layer. In one configuration, the coating layer provides a visual indication in response to a leak or unintentional spill of material on the coating layer of the platen 31. The coating layer may be configured to provide a color change upon contact with a cytotoxic material. The visual indication may be visually observable to a technician or user of the system. In other configurations, the visual indication may be observable by the image capture device 15, or additional image capture device, such as an infrared camera.


In a further configuration, the platen 31 may be formed of a transparent and/or translucent material which permits passage of light therethrough. In this configuration, the base portion 43 of the scale 9 may also include a light source 49 for illuminating a portion of the platen 31, such as by passing light through the platen 31 from a location underneath the platen 31. This allows for enhanced visual inspection of drug compounding related medications 37 and related supplies to ensure they are free of defects. For example, the illuminated platen 31 may allow for a technician to visualize coring found in fluid filled IV bags. The light source 49 may be tuned to a certain wavelength appropriate to illuminate certain particles present within the drug compounding related medications 37. In a certain configuration, the platen 31 may include regions that are opaque or substantially opaque and regions that are transparent, substantially transparent, translucent, and/or substantially translucent in order to selectively allow for illumination of certain portions of the platen 31.


In another configuration, a scanner may be housed within the base portion 43 of the scale 9. The scanner may be a barcode scanner optically configured to scan barcode labels present on drug compounding related medications 37 through the translucent and/or transparent portions of the platen 31. The barcode scanner may be configured to obtain information from the barcodes to determine the contents of the vials placed on the platen 31. In a further configuration, a barcode writer or an integrated label printer may be positioned within the base portion 43 of the scale 9 to write information to the label of a drug compounding related medication 37 placed on the platen 31. In one configuration, the barcode writer may be configured to write information to the label of a drug compounding medication 37 pertaining to compounding results, date, time, lot numbers, and the like.


In yet a further configuration, the platen 31 may be in wireless communication with one or more system components. For example, a wireless interface may be provided in electrical communication with the platen 31 which may read and/or write data to a device provided on top of the platen 31. The wireless interface may be a Bluetooth connection to a pump connected to a drug vessel provided on the platen 31. Information transferred thereby may include pump operating parameters, such as patient specific flow rate and volumes. Accordingly, an automatically programmed device may be provided without requiring further user handling steps.


In yet a further configuration, the platen 31 may be configured to exhibit a visual indicator, such as a color change, when a weight measured by the scale 9 is within a specified tolerance. For example, the platen 31 may be equipped with an illuminated display which is activated once the scale 9 is stabilized and the unit measured is within a specified tolerance for a given drug compounding process.


In operation, the pharmacist/technician may be prompted through a series of display screens provided on the display of the user interface 3 to take the following steps. First, the operator may scan a first barcode with the barcode scanner 13 on a drug compounding related medication 37 including a drug to be reconstituted to prepare the prescribed pharmaceutical compound. The medication container may be placed on the scale 9 at the time of the scan, or a user may first scan the barcode and subsequently place the drug compounding related medication 37 on the platen 31 of the scale 9. Once the weight stabilizes, the system verifies, using a mathematical algorithm, that the measured weight is meeting the weight target plus/minus a predetermined tolerance. In addition, the image capture device 15 takes an image of the drug compounding related medication 37 and displays it to the user on the display of the user interface 3. The user then removes the drug compounding related medication 37 from the platen 31 and the image is saved to the data record of the drug preparation. If the system cannot verify that the measured weight is within that target weight tolerance, the technician is required to re-perform this step until the correct weight is achieved.


Next, the technician scans a second barcode of a fluid container of fluid that is to be mixed with the drug to be reconstituted. As discussed above, the medication container containing the fluid may be placed on the scale 9 at the time of the scan, or a user may first scan the barcode and subsequently place the drug compounding related medication 37 on the platen 31 of the scale 9. Once the weight stabilizes, the image capture device 15 takes an image of the drug compounding related medication 37 and displays it to the user on the display of the user interface 3. The user then removes the drug compounding related medication 37 and the image is saved to the data record of the drug preparation. Again, if the system cannot verify that the measured weight is within that target weight tolerance, the technician is required to re-perform this step until the correct weight is achieved.


Thereafter, the user mixes the drug to be reconstituted with the fluid in the fluid container, both drug compounding related medications 37, by injecting the fluid from the fluid container into the medication container. The medication container is then returned to the platen 31 of the scale 9 and the weight of the medication container is verified. Once the weight is stabilized and verified, the image capture device 15 automatically takes an image of the completed drug compounding related medication 37 based on a signal received from the scale and displays the image on the display of the user interface 3. If the system cannot verify that the measured weight is within that target weight tolerance, the technician is required to re-perform this step until the correct weight is achieved.


If the technician decides that any of the above-described images are not meeting certain requirements, there is the option to request a new or additional image. Requesting another picture may automatically switch the image capture device 15 into a “live video mode” displayed at the user interface 3. The technician can now move the medication container on the scale 9 to a preferred position and trigger the image capture through the user interface 3. As before, the captured image will be shown at the user interface 3 and by removing the item from the scale 9, the technician accepts the image and the system automatically moves to the next compounding step.


Once the drug preparation is complete, the system may optionally print a barcode label for placement on the completed drug preparation that includes encoded information representing the name of the pharmaceutical and patient information.


The pharmacy preparation system 1 may function in conjunction with several sequential computer-implemented modules for preparing and administering a prescribed fluidic compound, such as a chemotherapy compound. The modules each include code allowing for input from a user, generating output, and calculating and determining instructions for the preparation and administration of the pharmaceutical compound that may be implemented on one or more processors. More specifically, the modules may allow for a physician to enter a prescription for a patient that is subsequently verified for accuracy, prepared based on computer-aided instruction, verified based on a weight measurement, and administered to a patient. The modules may, during the drug preparation: (i) retrieve the prescription information data input by the physician in the CPOE module from the intra-hospital network; (ii) verify that the scanned barcode corresponds with the prescription information; (iii) determine if the weight of the syringe and/or IV bag is within a predetermined threshold accuracy level for the amount of the pharmaceutical to be administered; (iv) determine what adjustments must be made if the weight is not accurate; and (v) transmit data relating to the weight of the syringe and/or IV bag back to the intra-hospital network. These modules and processes may be implemented on several networked computing devices, or an independent computing device having its own processor where data and information is communicated between the computing devices using any suitable wired or wireless communication protocol, such as, but not limited to Ethernet, WiFi, cellular, Bluetooth, or the like.


Accordingly, the present invention guides a pharmacist or technician through the different compounding steps to prepare a medication order in a pharmacy by giving step-by-step instructions on a computer screen and verifying the different compounding steps by measuring the weight of the compounded liquids with a scale. The measured weight is then analyzed with a mathematical algorithm which checks if the necessary compounding accuracy has been accomplished. Every time an item is placed on the scale, a picture of the top of the scale is captured to create a visual documentation trail of the compounding process. The pictures are stored together with the recorded measurements from the scale and the algorithm results in a log file. If a measured weight of a drug is not in the predefined tolerance range of the expected weight, the software generates instructions to change the amount of the drug to bring it within the acceptable tolerance range. The software will not proceed to the next compounding step as long as the required tolerance of the present step has not been accomplished.


EXAMPLES

Referring specifically to FIG. 7, a flow hood is shown having an inlet laminar flow condition of 70 ft/min and an outlet flow condition of 533 ft/min. The flow hood includes an inlet environmental pressure condition of 0 pa. The flow hood also includes a weighing surface of a scale and an enclosure that is being assessed. For purposes of modeling, a simplified half model environment is shown.


Referring to FIGS. 8A-13B, a series of computational fluid dynamic simulations are reflected showing the difference in airflow disturbance between different enclosure forms. For each of these figures, the flow trajectories and velocity contours were used as outputs and the identical environment, grid, and boundary conditions were used in each simulation. For each testing run, a 3 minute stability test was employed in which any oscillations that would occur in three minutes without being touched were documented. For the testing runs, a 100 g weight was used and 25 sample tests were run. The first stabilized value that the scale registered was recorded and two standard deviations were calculated and recorded as the accuracy.



FIGS. 8A-8B represent the air flow in a flow hood under idealized conditions with no enclosure present in the flow hood. The experimental assessment of the scale under these conditions was a stability of +/−0.00 g and an accuracy of +/−0.0229 g. To understand the design variables that are critical to scale stability, the typical airflow within a compounding hood, as shown in FIG. 8A, must be understood. In FIG. 8A, flow is directed from the top of the hood to the bottom and air exists in the two areas (seen in red) at the front and back of the hood. Near the platen of the scale, the air splits into alternative paths. With reference to FIG. 8B, since the enclosure housing is located above the scale, the enclosure housing is prone to create an airflow disturbance downstream which may result in scale instability and inaccuracy. Certain enclosure housing designs may be optimized to reduce this downstream airflow disturbance.



FIGS. 9A-9B represent the air flow in a flow hood with a large relatively blunt enclosure head present in the flow hood positioned above the scale. The experimental assessment of the scale under these conditions was a stability of +/−0.06 g and an unknown accuracy as the resulting scale readings were too unstable.



FIGS. 10A-10B represent the air flow in a flow hood with a medium sized relatively blunt enclosure head present in the flow hood positioned above the scale. The experimental assessment of the scale under these conditions was undetermined.



FIGS. 11A-11B represent the air flow in a flow hood with a medium sized relatively streamlined enclosure head present in the flow hood positioned above the scale. The experimental assessment of the scale under these conditions was a stability of +/−0.02 g and an accuracy of +/−0.0445 g.



FIGS. 12A-12B represent the air flow in a flow hood with a small sized very streamlined enclosure head present in the flow hood positioned above the scale. The experimental assessment of the scale under these conditions was a stability of +/−0.015 g and an accuracy of +/−0.0297 g.



FIGS. 13A-13B represent the air flow in a flow hood with a medium sized but shortened relatively streamlined enclosure head present in the flow hood positioned above the scale. The experimental assessment of the scale under these conditions was a stability of +/−0.01 g and an accuracy of +/−0.0153 g.


In each of FIGS. 8A-13B, the pressure and air speed of air within the flow hood is shown. The areas labeled B correspond to the smallest air speed and lowest pressure, corresponding to the least airflow disturbance. In contrast, the areas labeled R correspond to the greatest air speed and highest pressure, corresponding to the greatest airflow disturbance.


As shown in FIGS. 14-16, it is an objective of the present invention to minimize the quantity of turbulence that reaches the platen 31 of the scale 9. Maximizing the distance “Z” between the housing 17 and the platen 31 aids in allowing any disturbance created by the housing 17 to be swept toward the back of the hood prior to reaching the surface of the platen 31. Minimizing the distance “Y” aids in a similar fashion as this is directly related to the distance the disturbed air needs to travel prior to reaching the platen 31 of the scale 9. Minimizing “Y” and cross-sectional diameter a results in the smallest orthogonal area to the flow stream, thereby minimizing airflow disturbance. Maximizing the b/a cross-sectional ratio in conjunction with smooth curving of the housing 17 creates a streamlined profile in the direction of the flow stream. This will minimize the amount of air that becomes turbulent by gradually splitting the laminar airflow stream and subsequently allowing it to reconnect.


While specific embodiments of the invention have been described in detail, it will be appreciated by those skilled in the art that various modifications and alternatives to those details could be developed in light of the overall teachings of the disclosure. Accordingly, the particular arrangements disclosed are meant to be illustrative only and not limiting as to the scope of invention which is to be given the full breadth of the claims appended and any and all equivalents thereof.

Claims
  • 1. A system for preparing a pharmaceutical compound, comprising: a scale having a platen configured for placement of an object thereon;a supporting arm comprising a first end coupled to a portion of the scale and a second end extending to a position above the platen of the scale; andan enclosure housing comprising a first enclosure housing end and a second enclosure housing end, the first enclosure housing end attached to and extending from the second end of the supporting arm, the enclosure housing comprising dimensions such that a length defined by the first enclosure housing end and the second enclosure housing end is greater than a width of the enclosure housing anda height of each of the first and second enclosure housing end is greater than the width of the enclosure housing,the enclosure housing configured to house at least an image capture device,wherein the enclosure housing has a curved front profile and an upper portion comprising an upper surface having a portion that is concave along an axis defined by the first enclosure housing end and the second enclosure housing end, andwherein the height of at least a portion of the second end of the enclosure housing is greater than the height of at least a portion of the first end of the enclosure housing.
  • 2. The system of claim 1, wherein the enclosure housing further comprises a lower portion attached to the upper portion, at least one of the upper portion or lower portion attached to and extending from the second end of the supporting arm.
  • 3. The system of claim 1, wherein the second end of the enclosure housing extends over the platen of the scale, such that a field of view of the image capture device includes the platen.
  • 4. The system of claim 1, wherein the enclosure housing further comprises a barcode scanner.
  • 5. The system of claim 4, wherein the barcode scanner is angled with respect to the image capture device within the enclosure housing.
  • 6. The system of claim 5, wherein the barcode scanner is angled at a 45° angle with respect to a field of view of the image capture device.
  • 7. The system of claim 1, wherein the second end of the enclosure housing has a curved profile to minimize flow disturbance within a flow hood.
  • 8. A system for preparing a pharmaceutical compound, comprising: a computing device comprising a processor and a user interface providing an operator with instructions for preparing the pharmaceutical compound;a scale operatively coupled to the processor of the computing device; andan enclosure housing comprising a first enclosure housing end and a second enclosure housing end and housing an image capture device and a barcode scanner, the enclosure housing supported at the first enclosure housing end by a supporting arm and coupled to a portion of the scale,wherein the image capture device is operatively connected to the processor of the computing device and has a field of view positioned to capture an object positioned on the scale,wherein the first enclosure housing end has a height that is less than a height of the second enclosure housing end and the height of each of the first and second enclosure housing end is greater than a width of the enclosure housing, andwherein the enclosure housing has a curved front profile and an upper portion comprising an upper surface having a portion that is concave along an axis defined by the first enclosure housing end and the second enclosure housing end.
  • 9. The system of claim 8, wherein the barcode scanner is angled with respect to the image capture device within the enclosure housing.
  • 10. The system of claim 9, wherein the barcode scanner is angled at a 45° angle with respect to the field of view of the image capture device.
  • 11. The system of claim 8, wherein the enclosure housing is supported by the supporting arm such that the enclosure housing is positioned above the scale.
  • 12. The system of claim 8, wherein the enclosure housing further comprises a lower portion attached to the upper portion, and wherein the upper portion of the enclosure housing has a convex profile relative to a top surface of the scale.
  • 13. A system for preparing a pharmaceutical compound, comprising: a computing device comprising a user interface providing an operator with instructions for preparing the pharmaceutical compound; anda flow hood having positioned therein:a scale operatively connected to the user interface; andan enclosure housing comprising a camera positioned to capture an image of the scale during the preparation of the pharmaceutical compound, the enclosure having a width and a height, and wherein along an entire length of the enclosure, the enclosure height is greater than the enclosure width,wherein the enclosure housing has a curved front profile and an upper surface having a portion that is concave along an axis defined by the first enclosure housing end and the second enclosure housing end, andwherein the height of at least a portion of the second end of the enclosure housing is greater than the height of at least a portion of the first end of the enclosure housing.
  • 14. The system of claim 13, wherein the enclosure housing is positioned above the scale.
  • 15. The system of claim 13, wherein the enclosure housing further comprises a barcode scanner.
  • 16. The system of claim 15, wherein the barcode scanner is angled with respect to the camera within the enclosure housing.
  • 17. The system of claim 16, wherein the barcode scanner is angled at a 45° angle with respect to a field of view of an image capture device.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 14/847,534, filed Sep. 8, 2015, entitled “Aerodynamically Streamlined Enclosure for Input Devices of a Medication Preparation System”, which claims priority to U.S. Provisional Application Ser. No. 62/047,325, filed Sep. 8, 2014, entitled “Automated Visual Documentation Feature with Minimal User Input”, U.S. Provisional Application Ser. No. 62/072,160, filed Oct. 29, 2014, entitled “Enhanced Pharmacist Review Module for a System for Preparing a Pharmaceutical Compound”, U.S. Provisional Application Ser. No. 62/072,054, filed Oct. 29, 2014, entitled “Aerodynamically Streamlined Enclosure for Input Devices of a Medication Preparation System”, U.S. Provisional Application Ser. No. 62/078,067, filed Nov. 11, 2014, entitled “Aerodynamically Streamlined Enclosure for Input Devices of a Medication Preparation System”, and U.S. Provisional Application No. 62/077,968, filed Nov. 11, 2014, entitled “Enhanced Platen for Pharmaceutical Compounding”, the entire disclosures of each of which are hereby incorporated by reference.

US Referenced Citations (386)
Number Name Date Kind
3453422 Susor Jul 1969 A
3551353 Chen et al. Dec 1970 A
3584204 Susor Jun 1971 A
3587856 Lemelson Jun 1971 A
3627423 Knapp Dec 1971 A
3734286 Simjian May 1973 A
3914058 Knapp et al. Oct 1975 A
3965340 Renner et al. Jun 1976 A
3966332 Knapp et al. Jun 1976 A
3970643 Kee Woo et al. Jul 1976 A
4017157 van Riet Apr 1977 A
4063823 Grat Dec 1977 A
4087184 Knapp et al. May 1978 A
4165633 Raisanen Aug 1979 A
4273816 Tollette Jun 1981 A
4277089 Lockhart Jul 1981 A
4469146 Campbell et al. Sep 1984 A
4476381 Rubin Oct 1984 A
4549205 Misaki et al. Oct 1985 A
4628193 Blum Dec 1986 A
4653010 Figler et al. Mar 1987 A
4655026 Wigoda Apr 1987 A
4676650 Bjorndal et al. Jun 1987 A
4676776 Howson Jun 1987 A
4695954 Rose et al. Sep 1987 A
4733363 Yamada et al. Mar 1988 A
4790118 Chilcoate Dec 1988 A
4804273 Tondello et al. Feb 1989 A
4810243 Howson Mar 1989 A
4829650 Galard May 1989 A
4835372 Gombrich et al. May 1989 A
4839675 Owen Jun 1989 A
4847764 Halvorson Jul 1989 A
4853521 Claeys et al. Aug 1989 A
4857716 Gombrich et al. Aug 1989 A
4860899 McKee Aug 1989 A
4874764 Ueda et al. Oct 1989 A
4879650 Kurimoto et al. Nov 1989 A
4918604 Baum Apr 1990 A
4972657 McKee Nov 1990 A
5031642 Nosek Jul 1991 A
5038839 Morimoto et al. Aug 1991 A
5072798 Franklin Dec 1991 A
5084832 Yamada et al. Jan 1992 A
5088981 Howson et al. Feb 1992 A
5094786 Nagashima et al. Mar 1992 A
5153827 Coutre et al. Oct 1992 A
5182707 Cooper et al. Jan 1993 A
5184753 Horak Feb 1993 A
5260880 Tump Nov 1993 A
5261546 van der Grift Nov 1993 A
5272318 Rousso et al. Dec 1993 A
5308930 Tokutu et al. May 1994 A
5317506 Coutre et al. May 1994 A
5328208 Garrison Jul 1994 A
5337919 Spaulding et al. Aug 1994 A
5341077 Chen et al. Aug 1994 A
5341854 Zezulka et al. Aug 1994 A
5344043 Moulding et al. Sep 1994 A
5348061 Riley et al. Sep 1994 A
5365343 Knapp Nov 1994 A
5390796 Kerfoot, Jr. Feb 1995 A
5395174 Koch et al. Mar 1995 A
5401059 Ferrario Mar 1995 A
5404227 Sumita et al. Apr 1995 A
5405048 Rogers et al. Apr 1995 A
5416706 Hagenbuch May 1995 A
5442146 Bell et al. Aug 1995 A
5444480 Sumita Aug 1995 A
5444539 van der Grift Aug 1995 A
5468110 McDonald et al. Nov 1995 A
5480062 Rogers et al. Jan 1996 A
5502944 Kraft et al. Apr 1996 A
5508499 Ferrario Apr 1996 A
5516475 Wilson May 1996 A
5523560 Manique et al. Jun 1996 A
5568262 LaChapelle et al. Oct 1996 A
5583948 Shibayama Dec 1996 A
5593267 McDonald et al. Jan 1997 A
5597995 Williams et al. Jan 1997 A
5601314 Burns et al. Feb 1997 A
5643212 Coutre et al. Jul 1997 A
5651775 Walker et al. Jul 1997 A
5713485 Lift et al. Feb 1998 A
5719679 Shimizu et al. Feb 1998 A
5720154 Lasher et al. Feb 1998 A
5721433 Kosaka Feb 1998 A
5747744 Kraft et al. May 1998 A
5753868 Diem May 1998 A
5758095 Albaum et al. May 1998 A
5781442 Engleson et al. Jul 1998 A
5797515 Lift et al. Aug 1998 A
5833866 Brown Nov 1998 A
5841077 Kolaci Nov 1998 A
5841541 Dlugos Nov 1998 A
5907493 Boyer et al. May 1999 A
5940176 Knapp Aug 1999 A
5963136 O'Brien Oct 1999 A
5966457 Lemelson Oct 1999 A
5969317 Espy et al. Oct 1999 A
5979512 McGregor et al. Nov 1999 A
5990422 Komori et al. Nov 1999 A
6000828 Leet Dec 1999 A
6005959 Mohan et al. Dec 1999 A
6006828 Kluth et al. Dec 1999 A
6068156 Lift et al. May 2000 A
6113578 Brown Sep 2000 A
6181982 Yuyama et al. Jan 2001 B1
6202923 Boyer et al. Mar 2001 B1
6234964 Iliff May 2001 B1
6330491 Lion Dec 2001 B1
6347486 Badillet Feb 2002 B1
6364517 Yuyama et al. Apr 2002 B1
6384348 Haga et al. May 2002 B1
6438451 Lion Aug 2002 B1
6466879 Cantu et al. Oct 2002 B1
6473169 Dawley et al. Oct 2002 B1
6478147 Brander et al. Nov 2002 B1
6535637 Wootton et al. Mar 2003 B1
6542902 Dulong et al. Apr 2003 B2
6551391 Gerhardt et al. Apr 2003 B1
6564121 Wallace et al. May 2003 B1
6574580 Hamilton Jun 2003 B2
6581798 Lift et al. Jun 2003 B2
6605784 Eigenmann et al. Aug 2003 B2
6694334 DuLong et al. Feb 2004 B2
6711460 Reese Mar 2004 B1
6731324 Levy May 2004 B2
6738723 Hamilton May 2004 B2
6771369 Rzasa et al. Aug 2004 B2
6775602 Gordon, Jr. et al. Aug 2004 B2
6781689 Chiba Aug 2004 B2
6810355 Kreidler et al. Oct 2004 B1
6813473 Bruker Nov 2004 B1
6814255 Left et al. Nov 2004 B2
6816625 Lewis, Jr. et al. Nov 2004 B2
6873725 Xu Mar 2005 B2
6877530 Osborne et al. Apr 2005 B2
6915823 Osborne et al. Jul 2005 B2
6920094 Komaki Jul 2005 B2
6922652 Edwards et al. Jul 2005 B2
6937339 Yamazaki et al. Aug 2005 B2
6970094 Yamashita et al. Nov 2005 B2
6975924 Kircher et al. Dec 2005 B2
6990463 Walter et al. Jan 2006 B2
6995664 Darling Feb 2006 B1
6998542 Wallisch Feb 2006 B2
7006893 Hart et al. Feb 2006 B2
7015806 Naidoo et al. Mar 2006 B2
7017622 Osborne et al. Mar 2006 B2
7017623 Tribble et al. Mar 2006 B2
7028723 Alouani et al. Apr 2006 B1
7070097 Blanford et al. Jul 2006 B2
7096212 Fribble et al. Aug 2006 B2
7107106 Engelson et al. Sep 2006 B2
7117902 Osborne Oct 2006 B2
7128105 Fribble et al. Oct 2006 B2
7155396 Yuyama et al. Dec 2006 B2
7163035 Khan et al. Jan 2007 B2
7173197 Kasperek Feb 2007 B1
7194336 DiGianfilippo et al. Mar 2007 B2
7209891 Addy et al. Apr 2007 B1
7230529 Ketcherside, Jr. et al. Jun 2007 B2
7240699 Osborne et al. Jul 2007 B2
7262847 Goodall et al. Aug 2007 B2
7286997 Spector et al. Oct 2007 B2
7297108 Iliff Nov 2007 B2
7310143 Budd Dec 2007 B2
7317967 DiGianfilippo et al. Jan 2008 B2
7343224 DiGianfilippo et al. Mar 2008 B2
7343943 Khan et al. Mar 2008 B2
7357045 Rasmussen et al. Apr 2008 B2
7363115 Anderson et al. Apr 2008 B2
7375294 Kraft May 2008 B2
7376934 Steinrisser et al. May 2008 B2
7391515 Budd et al. Jun 2008 B2
7427002 Liff et al. Sep 2008 B2
7457685 D'Silva Nov 2008 B2
7478513 Baldwin Jan 2009 B2
7493263 Helmus et al. Feb 2009 B2
7499581 Tribble et al. Mar 2009 B2
7530497 Knowles et al. May 2009 B2
7536843 Djurle et al. May 2009 B2
7554042 Gregerson et al. Jun 2009 B2
7555557 Bradley et al. Jun 2009 B2
7560720 Voigt et al. Jul 2009 B2
7581953 Lehmann et al. Sep 2009 B2
7592553 Yuyama et al. Sep 2009 B2
7597247 Helmin et al. Oct 2009 B2
7599516 Limer et al. Oct 2009 B2
7610115 Rob et al. Oct 2009 B2
7620479 Kircher et al. Nov 2009 B2
7620563 Tornaquindici Nov 2009 B2
7620568 Parker-Malchak Nov 2009 B1
7631475 Baldwin et al. Dec 2009 B2
7633018 Leisinger et al. Dec 2009 B2
7636718 Steen et al. Dec 2009 B1
7643134 Berndt Jan 2010 B2
7651664 Appoldt et al. Jan 2010 B2
7681606 Khan et al. Mar 2010 B2
7698019 Moncrief et al. Apr 2010 B2
7706915 Mohapatra et al. Apr 2010 B2
7734478 Goodall et al. Jun 2010 B2
7753085 Tribble et al. Jul 2010 B2
7765108 Goodall et al. Jul 2010 B2
7769221 Shakes et al. Aug 2010 B1
7771659 Ziegler Aug 2010 B2
7801642 Ansari et al. Sep 2010 B2
7814731 Bender et al. Oct 2010 B2
7831393 Savva Nov 2010 B2
7831447 Schuman Nov 2010 B2
7837103 Suto Nov 2010 B2
7845551 Helmin et al. Dec 2010 B2
7847970 McGrady Dec 2010 B1
7860583 Condurso et al. Dec 2010 B2
7860730 Goodall et al. Dec 2010 B1
7861495 Yuyama et al. Jan 2011 B2
7873435 Yuyama et al. Jan 2011 B2
7886230 Monnier et al. Feb 2011 B2
7900658 Osborne et al. Mar 2011 B2
7913475 Khan et al. Mar 2011 B2
7913720 Tribble et al. Mar 2011 B2
7917329 Hamamoto Mar 2011 B2
7927313 Stewart et al. Apr 2011 B2
7930064 Popovich, Jr. et al. Apr 2011 B2
7930066 Eliuk et al. Apr 2011 B2
7930364 Ramaswamy et al. Apr 2011 B2
7937290 Bahir May 2011 B2
7938032 Fernando May 2011 B2
7941915 Yuyama et al. May 2011 B2
7956894 Akers et al. Jun 2011 B2
7964805 Yuyama et al. Jun 2011 B2
7991627 Hutchinson et al. Aug 2011 B2
7995831 Eller et al. Aug 2011 B2
8024913 Khan et al. Sep 2011 B2
8037659 Osborne et al. Oct 2011 B2
8041102 Yuyama et al. Oct 2011 B2
8073238 Nakanishi et al. Dec 2011 B2
8140349 Hanson et al. Mar 2012 B2
8140351 Tribble et al. Mar 2012 B2
8140395 Murphy et al. Mar 2012 B2
8151835 Khan et al. Apr 2012 B2
8191339 Fribble et al. Jun 2012 B2
8194129 Jones et al. Jun 2012 B2
8209941 Osborne et al. Jul 2012 B2
8219413 Martinez et al. Jul 2012 B2
8220503 Fribble et al. Jul 2012 B2
8224483 Ansari et al. Jul 2012 B1
8229763 Laughland et al. Jul 2012 B2
8234128 Martucci et al. Jul 2012 B2
8266878 Luciano, Jr. et al. Sep 2012 B2
8280549 Lift et al. Oct 2012 B2
8284305 Newcomb et al. Oct 2012 B2
8295582 Eller et al. Oct 2012 B2
8301410 Chu et al. Oct 2012 B2
8328082 Bochenko et al. Dec 2012 B1
8345989 Bresolin et al. Jan 2013 B1
8353318 Ranalletta et al. Jan 2013 B2
8374887 Alexander Feb 2013 B1
8374965 Friend et al. Feb 2013 B2
8396722 Tanimoto et al. Mar 2013 B2
8417539 Chapman et al. Apr 2013 B2
8433129 Nakanishi et al. Apr 2013 B2
8442298 Nakanishi et al. May 2013 B2
8448846 Needhan et al. May 2013 B2
8463622 Garms et al. Jun 2013 B2
8477989 Bresolin Jul 2013 B2
8489425 Moncrief et al. Jul 2013 B2
8551421 Luchinger Oct 2013 B2
8554579 Tribble et al. Oct 2013 B2
8571297 Eller et al. Oct 2013 B2
8571881 Rousso et al. Oct 2013 B2
8571886 Chudy et al. Oct 2013 B2
8678047 Tribble et al. Mar 2014 B2
8682047 Lang et al. Mar 2014 B2
8706522 Cohan et al. Apr 2014 B2
8740077 Needham et al. Jun 2014 B2
8763651 Stavsky et al. Jul 2014 B2
8775198 Wiener et al. Jul 2014 B2
8818821 Fioravanti Aug 2014 B2
8861816 Lang et al. Oct 2014 B2
8869297 Hanov et al. Oct 2014 B2
8881980 Magill Nov 2014 B2
8908163 Young et al. Dec 2014 B2
8958112 Matsui et al. Feb 2015 B2
8989895 Holman et al. Mar 2015 B2
9053616 Grabiner et al. Jun 2015 B2
9121751 Michael Sep 2015 B2
9138693 Aouad Sep 2015 B2
9240044 Okuda et al. Jan 2016 B2
20010048027 Walsh Dec 2001 A1
20020035412 Kircher et al. Mar 2002 A1
20020057339 Shoenfeld May 2002 A1
20020067411 Thompson et al. Jun 2002 A1
20020100762 Liff et al. Aug 2002 A1
20020139394 Bronson Oct 2002 A1
20020145042 Knowles et al. Oct 2002 A1
20030050731 Rosenblum Mar 2003 A1
20030050802 Jay et al. Mar 2003 A1
20030073349 Nagao et al. Apr 2003 A1
20030074223 Hickle et al. Apr 2003 A1
20030078849 Snyder Apr 2003 A1
20030105555 Lunak et al. Jun 2003 A1
20030107654 Ohmura Jun 2003 A1
20030136590 Gluvakov Jul 2003 A1
20030139701 White et al. Jul 2003 A1
20030140928 Bui et al. Jul 2003 A1
20030144878 Wilkes et al. Jul 2003 A1
20030158508 DiGianfilippo et al. Aug 2003 A1
20030179287 Kozic et al. Sep 2003 A1
20030204357 Hamilton Oct 2003 A1
20040017475 Akers et al. Jan 2004 A1
20040076318 Faeldt et al. Apr 2004 A1
20040143459 Engleson et al. Jul 2004 A1
20040150815 Sones et al. Aug 2004 A1
20040172289 Kozic et al. Sep 2004 A1
20040193454 Foote et al. Sep 2004 A1
20040204954 Lacko Oct 2004 A1
20040225528 Brock Nov 2004 A1
20050037485 Rodgers et al. Feb 2005 A1
20050080651 Morrison et al. Apr 2005 A1
20050086008 DiGianfilippo et al. Apr 2005 A1
20050130173 Leamon et al. Jun 2005 A1
20050197930 Polarine Sep 2005 A1
20060080041 Anderson et al. Apr 2006 A1
20060080177 Walter et al. Apr 2006 A1
20060106647 Brummel et al. May 2006 A1
20060136260 Ash et al. Jun 2006 A1
20060136261 Ash et al. Jun 2006 A1
20060136268 Ash et al. Jun 2006 A1
20060173714 Grotzinger Aug 2006 A1
20060200369 Batch et al. Sep 2006 A1
20060238346 Teller Oct 2006 A1
20060287884 Sandy et al. Dec 2006 A1
20070021929 Lemo et al. Jan 2007 A1
20070043473 Anderson et al. Feb 2007 A1
20070106425 Anderson et al. May 2007 A1
20070156707 Fuchs et al. Jul 2007 A1
20070162295 Akhtar et al. Jul 2007 A1
20070189597 Limer et al. Aug 2007 A1
20070228172 Knowles et al. Oct 2007 A1
20070239482 Finn et al. Oct 2007 A1
20080045811 Iliff Feb 2008 A1
20080047760 Georgitsis Feb 2008 A1
20080052120 Iliff Feb 2008 A1
20080052121 Iliff Feb 2008 A1
20080052122 Iliff Feb 2008 A1
20080052123 Iliff Feb 2008 A1
20080052130 Iliff Feb 2008 A1
20080052132 Iliff Feb 2008 A1
20080086326 Moura et al. Apr 2008 A1
20080105468 Ragazzini et al. May 2008 A1
20080125897 DiGanfilippo et al. May 2008 A1
20080195416 Tribble et al. Aug 2008 A1
20080312861 Casto et al. Dec 2008 A1
20090110019 Houde-Walter et al. Apr 2009 A1
20090154764 Khan et al. Jun 2009 A1
20090154789 Wolfe Jun 2009 A1
20090202108 Faeldt et al. Aug 2009 A1
20090265185 Finn et al. Oct 2009 A1
20090323108 Shimma Dec 2009 A1
20090326861 Langford et al. Dec 2009 A1
20100057264 Kircher et al. Mar 2010 A1
20100094653 Tribble Apr 2010 A1
20100324936 Vishnubhatla et al. Dec 2010 A1
20110029445 Whittacre et al. Feb 2011 A1
20110031038 Page Feb 2011 A1
20110073656 Detwiler Mar 2011 A1
20110184751 Holmes Jul 2011 A1
20110202366 Akers et al. Aug 2011 A1
20110234977 Verdooner Sep 2011 A1
20110267465 Alexander et al. Nov 2011 A1
20110307270 Berkelhamer et al. Dec 2011 A1
20120010840 Fankhauser et al. Jan 2012 A1
20120041778 Kraft Feb 2012 A1
20120065987 Farooq et al. Mar 2012 A1
20120330684 Jacobs et al. Dec 2012 A1
20130018356 Prince et al. Jan 2013 A1
20130054256 Holman et al. Feb 2013 A1
20130142406 Lang Jun 2013 A1
20130172863 Hakomori et al. Jul 2013 A1
20130194414 Poirier et al. Aug 2013 A1
20130271796 Landa Oct 2013 A1
20140025206 Matsui et al. Jan 2014 A1
20140157169 Kikin-Gil Jun 2014 A1
20150272320 Ranalletta et al. Oct 2015 A1
Foreign Referenced Citations (15)
Number Date Country
2477259 Sep 2003 CA
1803431 Jul 2007 EP
2379037 Feb 2003 GB
H04369822 Dec 1992 JP
2005211541 Aug 2005 JP
3186063 Sep 2013 JP
2013238493 Nov 2013 JP
201436791 Feb 2014 JP
8700659 Jan 1987 WO
03040980 May 2003 WO
2006095850 Sep 2006 WO
2008062485 May 2008 WO
2012008393 Jan 2012 WO
2012095279 Jul 2012 WO
2014065872 May 2014 WO
Non-Patent Literature Citations (63)
Entry
Scheraga, “Tech firms answer chain pharmacy's call for productivity”, Drug Store News, 2003, pp. 31-32.
ScriptPro, SP 200 with Collating Control Center Robotic Prescription Dispensing System, Available online as of Feb. 2004.
ScriptPro, SP 200 Robotic Prescription Dispensing System, Available online as of Feb. 2004.
ScriptPro, SP Automation Center 200TM (Space 200TM) Prescription Dispensing Automation Center, Available online as of Feb. 2004.
Seifert et al., “The Training of a Telepharmacist Addressing the Needs of Rural West Texas”, American Journal of Pharmaceutical Education, 2004, pp. 1-9, vol. 68, No. 3.
Texas Administrative Code, Title 22, Examining Boards.
Tracy et al., Telemedicine Technical Assistance Documents “A Guide to Getting Started in Telemedicine”, 2004, University of Missouri—School of Medicine, pp. 206-240.
Ukens, “Pharmacist shortage boosts telepharmacy”, Drug Topics, 2002, p. 53, vol. 146, No. 11.
United States Pharmacopeia, Chapter 797, The National Formulary, 2004, United States Pharmacopeial Convention, Inc., Rockville, MD.
Wills, “Drug Images and Drug Imprints: Delivering Tools for Accuracy in Your Pharmacy”, Insights, 2004, p. 7.
Woodall, “Remote Order Entry and Video Verifications: Reducing After-Hours Medication Error in a Rural Hospital”, Joint Commission Journal on Quality and Safety, 2004, pp. 442-447, vol. 30, No. 8.
Yahoo Mail, Oct. 1, 2002, pp. 1-3.
Young, “Loan repayments help pharmacists provide care in medically underserved areas”, American Journal Health-System Pharmacy, 2003, pp. 2186-2188, vol. 60.
Alexander, U.S. Appl. No. 11/056,511, filed Feb. 11, 2005.
Alexander, Office Action from U.S. Appl. No. 11/056,511, filed Apr. 8, 2008, pp. 1-12.
Alexander, Office Action from U.S. Appl. No. 11/056,511, filed Oct. 16, 2008, pp. 1-17.
Alexander, Office Action from U.S. Appl. No. 11/056,511, filed Apr. 13, 2009, pp. 1-14.
Alexander, Office Action from U.S. Appl. No. 11/056,511, filed Feb. 3, 2010, pp. 1-15.
Alexander, U.S. Appl. No. 13/097,575, filed Apr. 29, 2011.
Alexander, Notice of Allowance from U.S. Appl. No. 11/056,511, filed Dec. 24, 2012, pp. 1-16.
Anderson, “A Narrative on the History of the Development of Telepharmacy in North Dakota From the Board of Pharmacy's Perspective Recorded by Excerpts from Board Minutes”, North Dakota State Board of Pharmacy, 2006, pp. 1-5.
Angaran, “Telemedicine and telepharmacy: Current status and future implications”, American Journal of Health-System Pharmacy, 1999, pp. 1405-1426, vol. 56, No. 14.
Anonymous, “Pharmacy Annual Report-Chains covet customized pharmacy integration”, Drug Store News, 2003, pp. 73-75, vol. 25, No. 10.
Bynum et al., “The Effect of Telepharmacy Counseling on Metered-Dose Inhaler Technique among Adolescents with Asthma in Rural Arkansas”, Telemedicine Journal and e-Health, 2001, pp. 207-218, vol. 7, No. 3.
Cabral, Jr. et al., “Multimedia Systems for Telemedicine and Their Communications Requirements”, IEEE Communications Magazine, 1996, pp. 20-27.
Cardinal Health Pharmacy Resources, “Improving after-hour pharmacy services for a community hospital by a remote pharmacy”, 2003, Cardinal Health Inc., Houston Texas.
Casey et al., “Access to Rural Pharmacy Services In Minnesota, North Dakota, and South Dakota”, University of Minnesota Rural Health Research Center—Working Paper 36, 2001, pp. 1-76.
Casey et al., “Pharmacist Staffing and the Use of Technology in Small Rural Hospital: Implications for Medication Safety”, Upper Midwest Rural Health Research Center, 2005, pp. 1-43.
Clifton et al., “Provision of pharmacy services to underserved populations via remote dispensing and two-way videoconferencing”. Am. J. Health-Syst. Pharm, 2003, pp. 2577-2582, vol. 60.
Dakota Legislative Assembly, “Article 61-07 Hospital Pharmacy”, Apr. 1, 1988.
Dakota Legislative Assembly, “Article 61-02-08-08 Telepharmacy in Hospitals”, Dec. 1, 2003.
Dart, “Telepharmacy project offers a dose of technology”, North Dakota Living, 2003, pp. 10-11.
Dart, “Digital Doses-Telepharmacies save people in small towns and rural areas from having to drive hundreds of miles to fill a prescription”, Rural Electric, 2005, pp. 28-31.
Exactamix, “Compounding Solutions: An advanced system for multi-ingredient solution compounding”, 2016, Baxter International Inc., Illinois, pp. 1-12.
Felkey, “Tools for Interactive Telepharmacy”, Computer Talk, 2001, pp. 43-45.
Felkey, “Integrating Technology . . . at the Point of Care”, Insight, 2004, pp. 8-10.
First Consulting Group, “Regulatory Compliance News Summary now includes global pharmaceutical regulatory news”, 2004, pp. 1-7.
Frady, “What's New in RxCare Plus 17.2”, Insight, 2001, p. 14.
Ghent, “Pharmacists to digital to fight shortage”, Pharmacy Practice, 2004, pp. 47-48, vol. 20, No. 11.
Halversoan, “Innovative Healthcare Information Technology Solutions for Rural Americans”, Rural Wisconsin Health Cooperative, 2001, pp. 1-49.
Hix, “Outpatient Pharmacies “Booming”: An Inside Look at the Growth of an Industry”, Insight, 2004, pp. 14-17.
Horns, “cytostatic programs”, Pharmweb Internet Posting by Hank & Horns Software, Jan. 1999, pp. 1-3.
Kastango et al., “USP chapter 797: Establishing a practice standard for compounding sterile preparations in pharmacy”, American Journal Health-System Pharmacy, 2004, pp. 1928-1938, vol. 61.
Keeys et al., “Providing nighttime pharmaceutical services through telepharmacy”, American Journal Health-System Pharmacy, 2002, pp. 716-721, vol. 59.
Kosub, “Device allows pharmacy care in remote areas”, Pharmacy Practice, 2004, pp. 12-13, vol. 20, No. 10.
Koutnik, “The Pharmacy of Tomorrow”, Pharmacy Times, 2003, 3 pages.
Langham, “Taking Automation to New Levels”, Insight, 2002, pp. 4-5.
Lustig, “Medication error prevention by pharmacists—An Israeli solution”, Pharmacy World & Science, 2002, pp. 21-25, vol. 22, No. 1.
MacInnis et al., “Environmental Scan of Pharmacy Technicians”, 2001, Canadian Pharmacists Association, Ottawa, ON, pp. 1-16.
Morris, et al. “National survey of quality assurance activities for pharmacy-compounded sterile preparations”, American Journal Health-System Pharmacy, 2003, pp. 2567-2576, vol. 601.
Muller, “Electronic Prescribing What You Need to Know!”, Insight, 2002, pp. 10-12.
Muller, “Make Your Next Move QS/1's Premium Pharmacy”, Insight, 2003, pp. 13-15.
Napoli et al., “Picture archiving and communication in radiology”, Rays, 2003, vol. 28, No. 1, Abstract Only.
Nissen et al., “Can telepharmacy provide pharmacy services in the bush?”, Journal of Telemedicine and Telecare, 2003, pp. 39-41, vol. 9, Supplement 2.
North Dakota State Board of Pharmacy Practice Act 2003.
Parks, “Using central-fill to maximize dispensing”, Drug Store News, 2001, pp. 51, 75, vol. 23, No. 11.
Parks, “ATM-Style Drug Dispensers Taking Hold in Areas With Limited Pharmacist Services”, Pharmacy Practice News, 2004, 6 pages, vol. 31, No. 01.
Peterson, “The North Dakota Telepharmacy Project: Restoring and Retaining Pharmacy Services in Rural Communities”, Pharmacy Technology, 2004, pp. 28-39, vol. 20.
Petition for Inter Partes Review of U.S. Pat. No. 8,374,887, 2015.
Phillips, “Telepharmacy at Texas Tech”, Apr. 2003 Presentation, Texas Tech University Health Sciences Center.
“Reference Manual for Computer Aided Therapy for Oncology”, 2005, Cato Research, North Carolina, pp. 1-255.
Rouse et al., “White paper on pharmacy technicians 2002: Needed Changes can no longer wait”, American Journal Health-System Pharmacy, 2003, pp. 37-51, vol. 60.
“Rural Hospital Joins the Big Leagues with the Power of a Kodak PAS/Enterprise Information Management (EIM) Solution”, Kodak Medical Systems, 2005.
Related Publications (1)
Number Date Country
20200258228 A1 Aug 2020 US
Provisional Applications (5)
Number Date Country
62078067 Nov 2014 US
62077968 Nov 2014 US
62072054 Oct 2014 US
62072160 Oct 2014 US
62047325 Sep 2014 US
Continuations (1)
Number Date Country
Parent 14847534 Sep 2015 US
Child 16862174 US